U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

HER2 positive breast carcinoma

MedGen UID:
743175
•Concept ID:
C1960398
•
Neoplastic Process
Synonyms: ERBB2 Overexpressing Subtype of Breast Carcinoma; ERBB2 Overexpressing subtype of breast carcinoma; HER2 Overexpressing Breast Carcinoma; HER2 Overexpressing breast carcinoma; HER2 Overexpressing Subtype of Breast Carcinoma; HER2 Overexpressing subtype of breast carcinoma; HER2 Positive Breast Cancer; HER2 Positive breast cancer; HER2 Positive Breast Carcinoma; HER2-Positive Breast Carcinoma; HER2-positive carcinoma of breast; Her2-receptor positive breast cancer; Human epidermal growth factor 2 positive carcinoma of breast
SNOMED CT: HER2-positive carcinoma of breast (427685000); Human epidermal growth factor 2 positive carcinoma of breast (427685000)
 
Monarch Initiative: MONDO:0006244

Definition

A biologic subset of breast carcinoma defined by high expression of HER2, GRB7, and TRAP100, and by lack of expression of estrogen receptor (ER). [from NCI]

Professional guidelines

PubMed

Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Cheal SM, Xu H, Guo HF, Patel M, Punzalan B, Fung EK, Lee SG, Bell M, Singh M, Jungbluth AA, Zanzonico PB, Piersigilli A, Larson SM, Cheung NV
Theranostics 2018;8(18):5106-5125. Epub 2018 Oct 6 doi: 10.7150/thno.26585. PMID: 30429889Free PMC Article
Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases.
Zafir-Lavie I, Sherbo S, Goltsman H, Badinter F, Yeini E, Ofek P, Miari R, Tal O, Liran A, Shatil T, Krispel S, Shapir N, Neil GA, Benhar I, Panet A, Satchi-Fainaro R
J Control Release 2018 Dec 10;291:80-89. Epub 2018 Oct 17 doi: 10.1016/j.jconrel.2018.10.017. PMID: 30342077
Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
Haddley K
Drugs Today (Barc) 2013 Nov;49(11):701-15. doi: 10.1358/dot.2013.49.11.2020937. PMID: 24308017

Recent clinical studies

Etiology

Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma.
Zhao D, Fu X, Rohr J, Wang Y, Li M, Zhang X, Qin J, Xu M, Li C, Sun G, Wang Z, Guo S
Pathol Res Pract 2021 Dec;228:153677. Epub 2021 Oct 30 doi: 10.1016/j.prp.2021.153677. PMID: 34775151
ER staining levels affect HER2 staining and heterogeneity.
Akashi M, Yamaguchi R, Kusano H, Yamaguchi M, Akiba J, Kakuma T, Tanaka M, Akagi Y, Yano H
Breast Cancer 2021 May;28(3):720-726. Epub 2021 Jan 9 doi: 10.1007/s12282-020-01208-7. PMID: 33423217
Diverse histomorphology of HER2-positive breast carcinomas based on differential ER expression.
Akashi M, Yamaguchi R, Kusano H, Obara H, Yamaguchi M, Toh U, Akiba J, Kakuma T, Tanaka M, Akagi Y, Yano H
Histopathology 2020 Mar;76(4):560-571. Epub 2020 Feb 3 doi: 10.1111/his.14003. PMID: 31554015
Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.
Singla H, Kalra S, Kheterpal P, Kumar V, Munshi A
Curr Cancer Drug Targets 2017;17(4):344-356. doi: 10.2174/1568009616666161216094026. PMID: 27993117
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G
Oncotarget 2016 Aug 30;7(35):56295-56308. doi: 10.18632/oncotarget.10787. PMID: 27462779Free PMC Article

Diagnosis

Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma.
Narwadkar YS, Parghane RV, Sahu S, Lad S, Deep K, Wanage G, Suralkar T, Banerjee S, Gupta S, Basu S, Badwe RA
Clin Nucl Med 2024 Apr 1;49(4):e149-e155. Epub 2024 Feb 1 doi: 10.1097/RLU.0000000000005067. PMID: 38350067
Predictive markers for pathological complete response (pCR) after neo-adjuvant chemotherapy in HER2-positive breast carcinoma.
Van Bockstal MR, Dano H, Benhaddi N, Dubois D, Vanderveken J, Van Marcke C, Vandermeulen A, Duhoux FP, Vernaeve H, Berlière M, Galant C
Histol Histopathol 2024 Feb;39(2):153-164. Epub 2023 May 10 doi: 10.14670/HH-18-626. PMID: 37204204
rBC2LCN lectin as a potential probe of early-stage HER2-positive breast carcinoma.
Mawaribuchi S, Haramoto Y, Tateno H, Onuma Y, Aiki Y, Ito Y
FEBS Open Bio 2020 Jun;10(6):1056-1064. Epub 2020 May 5 doi: 10.1002/2211-5463.12852. PMID: 32237061Free PMC Article
Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.
Singla H, Kalra S, Kheterpal P, Kumar V, Munshi A
Curr Cancer Drug Targets 2017;17(4):344-356. doi: 10.2174/1568009616666161216094026. PMID: 27993117
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T
J Nucl Med 2016 Jan;57(1):27-33. Epub 2015 Oct 8 doi: 10.2967/jnumed.115.162024. PMID: 26449837

Therapy

Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma.
Narwadkar YS, Parghane RV, Sahu S, Lad S, Deep K, Wanage G, Suralkar T, Banerjee S, Gupta S, Basu S, Badwe RA
Clin Nucl Med 2024 Apr 1;49(4):e149-e155. Epub 2024 Feb 1 doi: 10.1097/RLU.0000000000005067. PMID: 38350067
Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma.
Zhao D, Fu X, Rohr J, Wang Y, Li M, Zhang X, Qin J, Xu M, Li C, Sun G, Wang Z, Guo S
Pathol Res Pract 2021 Dec;228:153677. Epub 2021 Oct 30 doi: 10.1016/j.prp.2021.153677. PMID: 34775151
Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.
Singla H, Kalra S, Kheterpal P, Kumar V, Munshi A
Curr Cancer Drug Targets 2017;17(4):344-356. doi: 10.2174/1568009616666161216094026. PMID: 27993117
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T
J Nucl Med 2016 Jan;57(1):27-33. Epub 2015 Oct 8 doi: 10.2967/jnumed.115.162024. PMID: 26449837
Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
Haddley K
Drugs Today (Barc) 2013 Nov;49(11):701-15. doi: 10.1358/dot.2013.49.11.2020937. PMID: 24308017

Prognosis

Molecular Classification of Breast Cancer.
Roy M, Fowler AM, Ulaner GA, Mahajan A
PET Clin 2023 Oct;18(4):441-458. Epub 2023 May 31 doi: 10.1016/j.cpet.2023.04.002. PMID: 37268505
Diverse histomorphology of HER2-positive breast carcinomas based on differential ER expression.
Akashi M, Yamaguchi R, Kusano H, Obara H, Yamaguchi M, Toh U, Akiba J, Kakuma T, Tanaka M, Akagi Y, Yano H
Histopathology 2020 Mar;76(4):560-571. Epub 2020 Feb 3 doi: 10.1111/his.14003. PMID: 31554015
Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.
Singla H, Kalra S, Kheterpal P, Kumar V, Munshi A
Curr Cancer Drug Targets 2017;17(4):344-356. doi: 10.2174/1568009616666161216094026. PMID: 27993117
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T
J Nucl Med 2016 Jan;57(1):27-33. Epub 2015 Oct 8 doi: 10.2967/jnumed.115.162024. PMID: 26449837
Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
Haddley K
Drugs Today (Barc) 2013 Nov;49(11):701-15. doi: 10.1358/dot.2013.49.11.2020937. PMID: 24308017

Clinical prediction guides

Molecular Classification of Breast Cancer.
Roy M, Fowler AM, Ulaner GA, Mahajan A
PET Clin 2023 Oct;18(4):441-458. Epub 2023 May 31 doi: 10.1016/j.cpet.2023.04.002. PMID: 37268505
Diverse histomorphology of HER2-positive breast carcinomas based on differential ER expression.
Akashi M, Yamaguchi R, Kusano H, Obara H, Yamaguchi M, Toh U, Akiba J, Kakuma T, Tanaka M, Akagi Y, Yano H
Histopathology 2020 Mar;76(4):560-571. Epub 2020 Feb 3 doi: 10.1111/his.14003. PMID: 31554015
Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.
Singla H, Kalra S, Kheterpal P, Kumar V, Munshi A
Curr Cancer Drug Targets 2017;17(4):344-356. doi: 10.2174/1568009616666161216094026. PMID: 27993117
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T
J Nucl Med 2016 Jan;57(1):27-33. Epub 2015 Oct 8 doi: 10.2967/jnumed.115.162024. PMID: 26449837
Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
Haddley K
Drugs Today (Barc) 2013 Nov;49(11):701-15. doi: 10.1358/dot.2013.49.11.2020937. PMID: 24308017

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • ClinVar
      Related medical variations

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...